HEALTHCARE · BIOTECHNOLOGY

Travere Therapeutics Inc (TVTX) Stock Price, Analysis & Trade Signals

$57.17-0.31 (-0.54%)

Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenodal, an orally administered synthetic form of chenodeoxycholic acid, used to dissolve radiolucent gallstones. Another key product is Cholbam, a cholic acid capsule prescribed for both children and adults suffering from bile acid synthesis disorders stemmi…

Market Cap
$2.49B
CEO
Eric Dube
Employees
385
IPO Date
2012-11-08
Website
www.travere.com

Tabs · Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics